Biocon Stock Jumped More Than 3% Today After US FDA Approval for Its Insulin Product

Bengaluru, July 16, 2025: Shares of Biocon Ltd (NSE: BIOCON, BSE: 532523) surged by 3.46% to ₹403.95 as of 09:30 AM IST today. This, after its subsidiary, Biocon Biologics Ltd, received approval from the U.S. Food and Drug Administration (USFDA) for Kirsty™ (Insulin Aspart-xjhz), a rapid-acting interchangeable insulin aspart injection.

At 10:52 a.m. , 16th July, its stock was up by 1.42% at Rs 396.

Stock Movement Snapshot

Biocon Biologics Secures FDA Approval for Kirsty™

Biocon Biologics Ltd announced that the USFDA has approved Kirsty™ (Insulin Aspart-xjhz), 100 units/mL, making it the first and only interchangeable biosimilar to NovoLog® (Insulin Aspart) in the U.S. Kirsty™ is a rapid-acting insulin analogue indicated to improve glycemic control in adults and children with diabetes mellitus. It is designed to act quickly, typically taken before meals, to manage post-meal blood sugar spikes.

Kirsty™ will be available in both single-patient-use prefilled pens and multiple-dose vials, suitable for subcutaneous injection and intravenous use.

“The FDA approval of Kirsty™, the first and only interchangeable biosimilar rapid-acting Insulin Aspart in the U.S., is a significant step forward in our efforts to make insulin more accessible and affordable,” said Shreehas Tambe, CEO & MD, Biocon Biologics Ltd.

Strategic Significance

This approval is a major win for Biocon for several reasons:

• Kirsty™ is now Biocon’s second FDA-approved interchangeable insulin biosimilar in the U.S., joining Semglee® (Insulin Glargine-yfgn Injection). An “interchangeable biosimilar” means it can be substituted for the reference product (NovoLog® in this case) by a pharmacist without requiring a new prescription, depending on state laws. This offers significant market access advantages and potential cost savings for patients.
• Sales of Insulin Aspart in the U.S. market were approximately $1.9 billion in 2024, indicating a substantial market opportunity for Kirsty™.
• The launch of Kirsty™ is expected to significantly enhance Biocon’s access to the vast U.S. diabetic population, which includes 38.4 million patients.

Market Metrics

Financial Snapshot

For the fiscal year ended March 31, 2025, Biocon reported a total revenue of ₹15,262 crore, marking a modest 3% increase year-on-year. The consolidated Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA) margin stood at 20.7%, a slight dip from 22.2% in fiscal 2024. Despite this, the company’s reported profit after tax (PAT) for FY25 was ₹1,429 crore, up from ₹1,298 crore in FY24, with the PAT margin increasing to 9.4% from 8.8%. As of March 31, 2025, Biocon’s total assets stood at ₹58,797.30 crore, with total equity reported at ₹21,644 crore. The company’s diversified revenue streams, particularly its biosimilars segment (contributing 58% of revenue in FY25), are key strengths, alongside generics (19%) and contract research services (23%).

What’s Next For Biocon?

The FDA approval of Kirsty™ marks a major breakthrough for Biocon in the high-value U.S. insulin market. As the first interchangeable biosimilar to NovoLog®, it offers strong substitution potential and access to a $1.9 billion market. This move strengthens Biocon’s biosimilars portfolio and supports future margin growth. The stock hitting a 52-week high reflects strong investor sentiment. Focus now shifts to the commercial launch timeline and market uptake in the U.S.

About Biocon

Biocon Ltd, listed since April 2004, is a leading innovation-led biopharmaceutical company based in India. Through its subsidiary Biocon Biologics, it offers a wide portfolio of biosimilars globally, serving over 5.8 million patients annually across 120+ countries. Biocon’s specialities include therapies for diabetes, cancer, and autoimmune diseases, with a strong pipeline of biosimilars and novel biologics.

Biocon’s FDA win for Kirsty™ reaffirms its global positioning in insulin biosimilars, providing a strong tailwind to investor sentiment as the stock eyes new highs.

REF: https://nsearchives.nseindia.com/corporate/Bioconlimited_16072025000015_CoverLetterpressrelease.pdf

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations